172 related articles for article (PubMed ID: 33984279)
1. Therapeutic targeting of RNA-binding protein by RNA-PROTAC.
Li X; Pu W; Chen S; Peng Y
Mol Ther; 2021 Jun; 29(6):1940-1942. PubMed ID: 33984279
[No Abstract] [Full Text] [Related]
2. Recent Advances of Degradation Technologies Based on PROTAC Mechanism.
Xiao M; Zhao J; Wang Q; Liu J; Ma L
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139095
[TBL] [Abstract][Full Text] [Related]
3. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
Li X; Song Y
J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
[TBL] [Abstract][Full Text] [Related]
4. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.
Raina K; Lu J; Qian Y; Altieri M; Gordon D; Rossi AM; Wang J; Chen X; Dong H; Siu K; Winkler JD; Crew AP; Crews CM; Coleman KG
Proc Natl Acad Sci U S A; 2016 Jun; 113(26):7124-9. PubMed ID: 27274052
[TBL] [Abstract][Full Text] [Related]
5. Caspase-7 uses RNA to enhance proteolysis of poly(ADP-ribose) polymerase 1 and other RNA-binding proteins.
Desroches A; Denault JB
Proc Natl Acad Sci U S A; 2019 Oct; 116(43):21521-21528. PubMed ID: 31586028
[TBL] [Abstract][Full Text] [Related]
6. Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?
Lospinoso Severini L; Bufalieri F; Infante P; Di Marcotullio L
Front Cell Dev Biol; 2022; 10():854352. PubMed ID: 35242765
[TBL] [Abstract][Full Text] [Related]
7. Proteolysis-targeting chimera molecules targeting SHP2.
Yu D; Zheng M; Liu Y; Chen L; Li H
Future Med Chem; 2022 Apr; 14(8):587-600. PubMed ID: 35297283
[TBL] [Abstract][Full Text] [Related]
8. G4-PROTAC: targeted degradation of a G-quadruplex binding protein.
Patil KM; Chin D; Seah HL; Shi Q; Lim KW; Phan AT
Chem Commun (Camb); 2021 Nov; 57(95):12816-12819. PubMed ID: 34783801
[TBL] [Abstract][Full Text] [Related]
9. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.
Lai AC; Toure M; Hellerschmied D; Salami J; Jaime-Figueroa S; Ko E; Hines J; Crews CM
Angew Chem Int Ed Engl; 2016 Jan; 55(2):807-10. PubMed ID: 26593377
[TBL] [Abstract][Full Text] [Related]
10. The state of the art of PROTAC technologies for drug discovery.
Wang C; Zheng C; Wang H; Zhang L; Liu Z; Xu P
Eur J Med Chem; 2022 May; 235():114290. PubMed ID: 35307618
[TBL] [Abstract][Full Text] [Related]
11. Native mass spectrometry and gas-phase fragmentation provide rapid and in-depth topological characterization of a PROTAC ternary complex.
Song JH; Wagner ND; Yan J; Li J; Huang RY; Balog AJ; Newitt JA; Chen G; Gross ML
Cell Chem Biol; 2021 Oct; 28(10):1528-1538.e4. PubMed ID: 34081921
[TBL] [Abstract][Full Text] [Related]
12. Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression.
Wang K; Dai X; Yu A; Feng C; Liu K; Huang L
J Exp Clin Cancer Res; 2022 Sep; 41(1):289. PubMed ID: 36171633
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in the Design and Development of Anticancer Molecules based on PROTAC Technology.
Mukhamejanova Z; Tong Y; Xiang Q; Xu F; Pang J
Curr Med Chem; 2021; 28(7):1304-1327. PubMed ID: 32164504
[TBL] [Abstract][Full Text] [Related]
14. Aptamer-PROTAC Conjugates (APCs) for Tumor-Specific Targeting in Breast Cancer.
He S; Gao F; Ma J; Ma H; Dong G; Sheng C
Angew Chem Int Ed Engl; 2021 Oct; 60(43):23299-23305. PubMed ID: 34240523
[TBL] [Abstract][Full Text] [Related]
15. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges.
Zeng S; Huang W; Zheng X; Liyan Cheng ; Zhang Z; Wang J; Shen Z
Eur J Med Chem; 2021 Jan; 210():112981. PubMed ID: 33160761
[TBL] [Abstract][Full Text] [Related]
16. Monitoring and deciphering protein degradation pathways inside cells.
Daniels DL; Riching KM; Urh M
Drug Discov Today Technol; 2019 Apr; 31():61-68. PubMed ID: 31200861
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in PROTACs for Drug Targeted Protein Research.
Yao T; Xiao H; Wang H; Xu X
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142231
[TBL] [Abstract][Full Text] [Related]
18. Specific MHC-I Peptides Are Induced Using PROTACs.
Jensen SM; Potts GK; Ready DB; Patterson MJ
Front Immunol; 2018; 9():2697. PubMed ID: 30524438
[TBL] [Abstract][Full Text] [Related]
19. Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta.
Bai N; Miller SA; Andrianov GV; Yates M; Kirubakaran P; Karanicolas J
J Chem Inf Model; 2021 Mar; 61(3):1368-1382. PubMed ID: 33625214
[TBL] [Abstract][Full Text] [Related]
20. Leukocyte protease binding to nucleic acids promotes nuclear localization and cleavage of nucleic acid binding proteins.
Thomas MP; Whangbo J; McCrossan G; Deutsch AJ; Martinod K; Walch M; Lieberman J
J Immunol; 2014 Jun; 192(11):5390-7. PubMed ID: 24771851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
